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S266 Poster Session Imonocytes. While many studies have shown that MSCs impair the
differentiation of monocytes into dendritic cells and macrophages,
there are few articles showing the interaction between MSCs and
monocytes and none of them have addressed the question of mono-
cyte subsets modulation.
Methods: To better understand the mechanism behind the benefit
ofMSCs infusion for graft-versus-host treatment throughmonocytes
involvement, we performedmixed leucocytes reactions (MLR) in the
presence or absence of MSCs. After three or seven days, cultures
were analyzed by flow cytometry using different approaches.
Results:MSCs induced changes in monocyte phenotype in a MLR.
This alteration was accompanied by an increase in monocyte count-
ing and in CD14 expression. MSCs induced monocyte alterations
even without contact, although the parameters above weremore pro-
nounced with cell-cell contact. Moreover, the presence of MSCs im-
paired MHC I and II, CD11c, CCR5 expression and induced CD14
and CD64 expression on monocytes. These alterations were accom-
panied by a decrease in IL-1b and IL-6 production by these mono-
cytes but no change was observed taking into account the
phagocytosis capacity of these monocytes.
Conclusions: Our results suggest that MSCs impair the dif-
ferentiation of CD14++CD16-CD64+ classical monocytes into
CD14++CD16+CD64++ activate monocytes, having a role even ear-
lier than the differentiation of monocytes into dendritic cells and
macrophages.
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EFFECTIVE MOBILIZATION OF MESENCHYMAL STEM CELLS IN C57BL/6
MICE UTILIZING SINGLE AGENT PLERIXAFOR (AMD3100) OR IN COMBI-
NATION WITH NEUPOGEN (G-CSF)
Frank, R.R.1, Jagan, S.1, Paganessi, L.A.1, McNulty, M.A.2,
Sumner, D.R.2, Fung, H.C.1, Gregory, S.A.1, Christopherson, K.W.1,2
1Rush University Medical Center, Chicago, IL; 2Rush University Medical
Center, Chicago, IL
Introduction:Mesenchymal stem cells (MSC) are a rare population
of cells that have the ability to form muscle, bone, cartilage, and ad-
ipose. MSC can be obtained from the bone marrow (BM). Strategies
to mobilize MSC into the peripheral blood (PB) where they can be
easily collected would be of therapeutic benefit but there is a lack
of consensus on effective strategies to mobilize MSC.
Methods: During a screen in C57BL/6 mice, subcutaneous (SC)
injections of neupogen (G-CSF) or plerixafor (AMD3100) were
identified as agents that mobilize MSC. Subsequently, neupogen
(G-CSF, 50mg/kg SC twice a day for 4 days) and plerixafor
(AMD3100, 5mg/kg SC, once 1 hr prior) were assessed in individual
mice (N 5 5) as single agents or in combination. PB and BM were
collected and plated for colony formation in 5%CO2 5%O2 for 7
days.MSC colonies were scored as colony formation units-fibroblast
(CFU-F total, large, & small) in parallel with hematopoietic progen-
itors (CFU-GM, BFU-E, and CFU-GEMM). Data is presented as
colonies /mL PB or /femur 6 SEM and analyzed using Mann-
Whitney U test.
Results: Analysis of data showed that, as compared to saline, treat-
ment with G-CSF and to a greater extent AMD3100 resulted in mo-
bilization of total CFU-F (large & small CFU-F) into the PB
(5.562.5, 22.165.3, and 135.8611.5 CFU-F/mL respectively
(p\0.05). Combination G-CSF+AMD3100 mobilized at levels
(110.565.1 CFU-F/mL) not statistically different than single agent
AMD3100 (p\0.05). Analysis of the large CFU-F colonies revealed
that a significant number of large CFU-F were mobilized with
AMD3100 or combination G-CSF+AMD3100 (p\0.05), but not
G-CSF alone. In the BM, the total number of CFU-F, as compared
to saline, was decreased in response to G-CSF or G-CSF +
AMD3100, but not single agent AMD3100 (p\0.05). The response
of hematopoietic progenitor mobilization to the agents tested was as
expected: G-CSF, AMD3100, or G-CSF+AMD3100 mobilize
CFU-GM, BFU-E, and CFU-GEMM into the PB with the greatest
level of mobilization resulting from G-CSF+AMD3100 (p\0.05).
Conclusion: Single agent AMD3100 administered SC is effective at
mobilizing mouse MSC (total CFU-F or large CFU-F) with no
additional enhancement from combination G-CSF+AMD3100.G-CSF treatment, alone or in combination, depletes MSC in the
bonemarrowwhereas treatment with AMD3100 does not. This sug-
gests that use of single agent plerixafor (AMD3100) may be an effec-
tive strategy to mobilize MSC for use in the context of regenerative
medicine.
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EPAC ACTIVATION REGULATES HUMAN MESENCHYMAL STEM CELLS
MIGRATION AND ADHESION
Yu, J.-L.1, Chung, S.K.2, Chan, G.C.-F.1 1The University of Hong Kong,
Hong Kong Special Administration Region, China; 2The University of
Hong Kong, Hong Kong Special Administration Region, China
Currently, one of the challenges confronted by the clinical appli-
cations of human mesenchymal stem cells (hMSCs) is how to en-
hance the homing and engraftment of hMSCs to the target tissues
with high efficiency. To overcome such barrier, mechanisms respon-
sible for the hMSCs homing and engraftment are one of the key re-
search foci. As of now, the exact mechanism and soluble factors
involved in migration and adhesion of hMSCs have not been com-
pletely unfolded. Exchange protein directly activated by cAMP
(Epac), a novel protein discovered in cAMP signaling pathway, at-
tracts our attention due to its potential role in regulating cells adhe-
sion and migration by triggering the downstream Rap family
signaling cascades.However, the exact biological role of Epac in cells
homing remains elusive and even controversial. Our study aimed to
evaluate the regulatory effects of Epac in the homing process of
hMSCs. We confirmed that hMSCs expressed functional Epac. In
addition, Epac activation stimulated by specific analogue enhanced
the adhesion and migration capacities of hMSCs significantly.
Such homing enhancement effects were associated with correspond-
ing morphological changes induced by Epac. The Epac activation
was further found to be contributed directly to the chemotactic re-
sponses induced by stromal cell derived factor-1 (SDF-1) which is
a known crucial chemokine in regulating hMSCs homing. These
findings suggested Epac is connected to the SDF-1 signaling cas-
cades. In conclusion, our study revealed that Epac plays a role in
hMSCs homing by promoting adhesion, migration and also by en-
hancing chemotactic effect induced by SDF-1. Appropriate manipu-
lation of Epac may enhance the homing and engraftment of hMSCs
and facilitate the future clinical applications of hMSCs.171
ROLE OF NFATC2 IN PROLIFERATION AND DIFFERENTIATION OF HUMAN
CD34+ HEMATOPOIETIC STEM CELLS
Salhotra, A., Yang, S., Paul, T., Lu, H., Huang, X., Wendling, A.,
Farmer, J., Masri, H.E.I., Laughlin, M.J. University of Virginia,
Charlottesville, VA
Background: Cyclosporine-A (CSA) inhibits NFATc2 activation
and is effective in management of graft versus host disease
(GVHD). Little is known of the role of NFATc2 transcription factor
and its inhibition, in affecting differentiation and proliferation of
CD34+ HSC’s (Hematopoietic Stem Cells).
Methods:We used Ficoll density gradient method to obtain Mono-
nuclear Cell (MNC) from human cord blood units (provided by Pa-
blo Rubinstein, MD, New York Blood Center). MNC’s were
enriched for CD34+ HSC’s using magnetic bead separation (Auto
Macs, Miltenyi) which were plated at density of 60,000 cells / ml
in serum free media with IL-3 (5ng/ml), FLT-3L (100 ng/ml),
SCF (50 ng/ml), G-CSF (30 ng/ml) and GM-CSF (5ng/ml). Cells
were cultured under normoxic conditions for 7 days at 37.0C with
5%CO2. HSC proliferation and differentiation was studied in pres-
ence and absence of CSA.
Results:Flow cytometry analysis of HSC’s grown in absence of CSA
showed high CD 34 (84.7%) and low CD33/ HLA-DR (0.57% and
5.71 % respectively) expression on Day 0 of culture. In presence of
CSA at 2mM concentration, we noted a more rapid rise of CD33
(41.0% versus 28.1%) HLA-DR (44.4% versus 29.1%) and CD 71
(12 % Vs 24.4%) markers by day 7. No difference was noted in total
cell count in CSA treated 701,666.66 7637 (mean and SD) and un-
treated 643,333 6 5166 conditions.
